Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis

K. O'Donnell, B. Keogh, A. Cantin, Ronald Crystal

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology characterized by inflammation of the lower respiratory tract and injury and fibrosis of the lung parenchyma. Neutrophils are a significant component of the alveolitis of IPF, and are known to have a potent armamentarium of mediators capable of damaging the lung parenchyma. To evaluate the ability of 2 pharmacologic agents, corticosteroids and cyclophosphamide, to suppress the neutrophil component of the inflammation of IPF, bronchoalveolar lavage was used to monitor those patients with active disease (> 10% neutrophils recovered by lavage). Those patients treated with corticosteroids alone showed no suppression in the neutrophil component of the alveolitis after 3 months and at 6 months of therapy (p > 0.8, both compared to before therapy). In marked contrast, patients treated with cyclophosphamide, alone or with corticosteroids, showed a significant reduction in the neutrophil alveolitis at 3 months (cyclophosphamide alone, p < 0.01; cyclophosphamide and corticosteroids, p < 0.02; both compared to before therapy) and at 6 months (cyclophosphamide alone, p < 0.01; compared to before therapy). Pulmonary function tests at the beginning and end of the study were not different in any of the treatment groups. Thus, cyclophosphamide, alone or in combination with corticosteroids, is much more effective than corticosteroids alone in suppressing the neutrophil component of the inflammation of IPF. Whether or not this effect of cyclophosphamide will result in overall stabilization or improvement of the disease will require a larger, likely multicenter, trial.

Original languageEnglish
Pages (from-to)288-292
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume136
Issue number2
DOIs
Publication statusPublished - 1 Jan 1987
Externally publishedYes

Fingerprint

Idiopathic Pulmonary Fibrosis
Cyclophosphamide
Neutrophils
Adrenal Cortex Hormones
Inflammation
Therapeutics
Therapeutic Irrigation
Respiratory Function Tests
Interstitial Lung Diseases
Lung Injury
Bronchoalveolar Lavage
Respiratory System
Multicenter Studies
Fibrosis
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. / O'Donnell, K.; Keogh, B.; Cantin, A.; Crystal, Ronald.

In: American Review of Respiratory Disease, Vol. 136, No. 2, 01.01.1987, p. 288-292.

Research output: Contribution to journalArticle

@article{368b158be76247c8aaf24611e4e2c850,
title = "Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology characterized by inflammation of the lower respiratory tract and injury and fibrosis of the lung parenchyma. Neutrophils are a significant component of the alveolitis of IPF, and are known to have a potent armamentarium of mediators capable of damaging the lung parenchyma. To evaluate the ability of 2 pharmacologic agents, corticosteroids and cyclophosphamide, to suppress the neutrophil component of the inflammation of IPF, bronchoalveolar lavage was used to monitor those patients with active disease (> 10{\%} neutrophils recovered by lavage). Those patients treated with corticosteroids alone showed no suppression in the neutrophil component of the alveolitis after 3 months and at 6 months of therapy (p > 0.8, both compared to before therapy). In marked contrast, patients treated with cyclophosphamide, alone or with corticosteroids, showed a significant reduction in the neutrophil alveolitis at 3 months (cyclophosphamide alone, p < 0.01; cyclophosphamide and corticosteroids, p < 0.02; both compared to before therapy) and at 6 months (cyclophosphamide alone, p < 0.01; compared to before therapy). Pulmonary function tests at the beginning and end of the study were not different in any of the treatment groups. Thus, cyclophosphamide, alone or in combination with corticosteroids, is much more effective than corticosteroids alone in suppressing the neutrophil component of the inflammation of IPF. Whether or not this effect of cyclophosphamide will result in overall stabilization or improvement of the disease will require a larger, likely multicenter, trial.",
author = "K. O'Donnell and B. Keogh and A. Cantin and Ronald Crystal",
year = "1987",
month = "1",
day = "1",
doi = "10.1164/ajrccm/136.2.288",
language = "English",
volume = "136",
pages = "288--292",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis

AU - O'Donnell, K.

AU - Keogh, B.

AU - Cantin, A.

AU - Crystal, Ronald

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology characterized by inflammation of the lower respiratory tract and injury and fibrosis of the lung parenchyma. Neutrophils are a significant component of the alveolitis of IPF, and are known to have a potent armamentarium of mediators capable of damaging the lung parenchyma. To evaluate the ability of 2 pharmacologic agents, corticosteroids and cyclophosphamide, to suppress the neutrophil component of the inflammation of IPF, bronchoalveolar lavage was used to monitor those patients with active disease (> 10% neutrophils recovered by lavage). Those patients treated with corticosteroids alone showed no suppression in the neutrophil component of the alveolitis after 3 months and at 6 months of therapy (p > 0.8, both compared to before therapy). In marked contrast, patients treated with cyclophosphamide, alone or with corticosteroids, showed a significant reduction in the neutrophil alveolitis at 3 months (cyclophosphamide alone, p < 0.01; cyclophosphamide and corticosteroids, p < 0.02; both compared to before therapy) and at 6 months (cyclophosphamide alone, p < 0.01; compared to before therapy). Pulmonary function tests at the beginning and end of the study were not different in any of the treatment groups. Thus, cyclophosphamide, alone or in combination with corticosteroids, is much more effective than corticosteroids alone in suppressing the neutrophil component of the inflammation of IPF. Whether or not this effect of cyclophosphamide will result in overall stabilization or improvement of the disease will require a larger, likely multicenter, trial.

AB - Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology characterized by inflammation of the lower respiratory tract and injury and fibrosis of the lung parenchyma. Neutrophils are a significant component of the alveolitis of IPF, and are known to have a potent armamentarium of mediators capable of damaging the lung parenchyma. To evaluate the ability of 2 pharmacologic agents, corticosteroids and cyclophosphamide, to suppress the neutrophil component of the inflammation of IPF, bronchoalveolar lavage was used to monitor those patients with active disease (> 10% neutrophils recovered by lavage). Those patients treated with corticosteroids alone showed no suppression in the neutrophil component of the alveolitis after 3 months and at 6 months of therapy (p > 0.8, both compared to before therapy). In marked contrast, patients treated with cyclophosphamide, alone or with corticosteroids, showed a significant reduction in the neutrophil alveolitis at 3 months (cyclophosphamide alone, p < 0.01; cyclophosphamide and corticosteroids, p < 0.02; both compared to before therapy) and at 6 months (cyclophosphamide alone, p < 0.01; compared to before therapy). Pulmonary function tests at the beginning and end of the study were not different in any of the treatment groups. Thus, cyclophosphamide, alone or in combination with corticosteroids, is much more effective than corticosteroids alone in suppressing the neutrophil component of the inflammation of IPF. Whether or not this effect of cyclophosphamide will result in overall stabilization or improvement of the disease will require a larger, likely multicenter, trial.

UR - http://www.scopus.com/inward/record.url?scp=0023581694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023581694&partnerID=8YFLogxK

U2 - 10.1164/ajrccm/136.2.288

DO - 10.1164/ajrccm/136.2.288

M3 - Article

C2 - 3619187

AN - SCOPUS:0023581694

VL - 136

SP - 288

EP - 292

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -